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Background: Atrial fibrillation (AF) patients frequently require anticoagulation with vitamin K antagonists (VKAs) to
prevent thromboembolic events, but their use increases the risk of hemorrhage. We evaluated time spent in
therapeutic range (TTR), proportion of international normalized ratio (INR) measurements in range (PINRR), adverse
events in relation to INR, and predictors of INR control in AF patients using VKAs.
Methods: We searched MEDLINE, CENTRAL and EMBASE (1990-June 2013) for studies of AF patients receiving
adjusted-dose VKAs that reported INR control measures (TTR and PINRR) and/or reported an INR measurement
coinciding with thromboembolic or hemorrhagic events. Random-effects meta-analyses and meta-regression
were performed.
Results: Ninety-five articles were included. Sixty-eight VKA-treated study groups reported measures of INR control,
while 43 studies reported an INR around the time of the adverse event. Patients spent 61% (95% CI, 59–62%), 25%
(95% CI, 23–27%) and 14% (95% CI, 13-15%) of their time within, below or above the therapeutic range. PINRR
assessments were within, below, and above range 56% (95% CI, 53–59%), 26% (95% CI, 23–29%) and 13% (95% CI,
11-17%) of the time. Patients receiving VKA management in the community spent less TTR than those managed by
anticoagulation clinics or in randomized trials. Patients newly receiving VKAs spent less TTR than those with prior VKA
use. Patients in Europe/United Kingdom spent more TTR than patients in North America. Fifty-seven percent (95% CI,
50-64%) of thromboembolic events and 42% (95% CI, 35 – 51%) of hemorrhagic events occurred at an INR <2.0
and >3.0, respectively; while 56% (95% CI, 48-64%) of ischemic strokes and 45% of intracranial hemorrhages
(95% CI, 29-63%) occurred at INRs <2.0 and >3.0, respectively.
Conclusions: Patients on VKAs for AF frequently have INRs outside the therapeutic range. While, thromboembolic and
hemorrhagic events do occur patients with a therapeutic INR; patients with an INR <2.0 make up many of the cases of
thromboembolism, while those >3.0 make up many of the cases of hemorrhage. Managing anticoagulation outside of
a clinical trial or anticoagulation clinic is associated with poorer INR control, as is, the initiation of therapy in the
VKA-naïve. Patients in Europe/UK have better INR control than those in North America.
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Atrial fibrillation (AF) is the most common sustained
cardiac arrhythmia worldwide and increases the risk of
ischemic stroke by nearly 5-fold [1,2]. Studies have demon-
strated that adjusted-dose vitamin K antagonists (VKAs)
significantly decrease the risk of stroke in AF patients
versus placebo or aspirin therapy [3,4]. However, VKA
use can be challenging given the narrow therapeutic
international normalized ratio (INR) range, requirement
for periodic INR monitoring, high inter-patient variability
in response, numerous drug and food interactions and
risks related to non-adherence [5].
In previous meta-analyses [6-9] the quality of anticoa-
gulation control with VKAs has proven to be poor; with
an estimated time spent in the therapeutic INR range
(TTR) between 55% and 64%. Numerous study-level fac-
tors (e.g., VKA dosing setting) have been shown to be
an important determinant of the quality of INR control.
Thromboembolic events may occur more frequently at
an INR <2.0 and major hemorrhagic events at an INR >3.0
[10]. No previous meta-analyses have examined INR con-
trol in VKA-experienced as compared to naïve patients as
a study-level factor, not all analyses have looked at AF
alone, and few have assessed the percentage of INRs in
therapeutic range (PINRR) as a quality measure of INR
control. Moreover, there has been a substantive increase in
the number of studies assessing INRs in patients with AF
receiving VKAs in the past few years, lending more power
and validity to a systematic assessment of INR control be-
ing conducted now.
The primary objective of this systematic review with
meta-analyses and meta-regression analyses was to as-
sess VKA INR control in AF patients and the effect of
selected study-level factors (including prior VKA treatment
experience) on TTR and the PINRR, and to evaluate the
relationship between the proportion of VKA-associated
hemorrhagic and thromboembolic events that occurred
when the INR was above or below the therapeutic range.
Methods
Study selection
A systematic review of MEDLINE, CENTRAL and
EMBASE (from 1990 through June 2013) was performed.
Our search strategy for Medline is provided in the
Additional file 1. Two investigators reviewed all poten-
tially relevant articles independently, with disagreement
resolved by a third investigator. Studies were selected for
inclusion on the basis of the following criteria: English
full-text randomized controlled trials (RCT), prospective
cohort studies or retrospective analyses; contained ≥50
patients in each treatment group; conducted in adult
patients (≥18 years of age) receiving dose-adjusted VKA
with AF as their primary reason for anticoagulation;
and INR control reported as TTR, PINRR or report anINR measurement at (within 48 hours of the event) or
near (more than 48 hours from the event) the time of a
hemorrhagic or thromboembolic event. Studies were
excluded if the duration of study was <3 months, the
target INR range was other than 2.0 to 3.0, or patient popu-
lation overlapped with another study. Manual backward
citation tracking of references from identified studies and
review articles was also performed to identify additional
relevant studies.
Data abstraction
Two investigators used a common data abstraction tool,
but independently abstracted all data. If a disagreement
arose it was resolved by a third investigator. The following
study-level information was obtained: author identification,
year of publication (1990–2000, 2001–2007 or 2008–2013),
whether patients were VKA-naïve (<30% of the population
receiving a VKA prior to entering the study) or experienced
(>70% of the population receiving a VKA prior to enter-
ing the study), geographic location of the study (Europe/
United Kingdom (UK), Asia, North America, multinational
or other), duration of VKA treatment , specific VKA used,
interpolation method, whether patients were utilizing VKA
self-management to monitor INR control and the study set-
ting (anticoagulation clinic, RCT, or community/standard
practice). The setting was designated using the following
definitions: an anticoagulation clinic, if the study took place
in an anticoagulation clinic or if the stated role of the study
clinicians in patient care was limited to managing anti-
coagulation; a randomized trial if random allocation
was employed to assign subjects to receive warfarin or
another non-warfarin therapy; and all others were clas-
sified as community practice.
Measures of INR control and outcomes were abstracted
from each study including TTR, time spent above range,
time spent below range, PINRR, proportion of INR
measurements above and below therapeutic range and
clinical outcomes of major hemorrhage and thrombo-
embolic events. Major hemorrhages included intracranial
hemorrhage (ICH) and extracranial bleeding (bleeding
requiring hospitalization, blood transfusion or surgical
treatment or occurring at a critical anatomical location).
All thromboembolic events were abstracted including
ischemic stroke, systemic emboli, venous thromboembol-
ism and myocardial infarction. INR measurements at or
near each thromboembolic and hemorrhagic event were
abstracted when reported.
Statistical analysis
TTR and PINRR for each study group, as well as the
time/proportions below and above range for these measures
were expressed as an incidence density using a person-time
approach. The numerator was calculated as the proportion
of time that the group spent within, below or above the
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or above range multiplied by person-years of follow-up.
The denominator was the total person-years of observation
for each study group (or the mean/median observation time
multiplied by the number of patients in each study group, if
person-years of follow-up for the VKA arm(s) in a study
was not reported). Ninety-five percent confidence intervals
(CIs) were calculated for each incidence density using the
Wilson score method without continuity correction. For
the purposes of these analyses, all studies were pooled using
a random-effects model.
In order to determine how study–level factors influ-
enced TTR or PINRR, both subgroup and meta-regression
analyses were conducted. Meta-regression analysis allows
evaluating the effect of any given influencing factor inde-
pendent of the effect of other aspects. A multiple linear
mixed method model using both random- and fixed-effects
was utilized for meta-regression, which was weighted by
the inverse of the variance of TTR or PINRR. Fixed-effects
were assumed for study-level factors, including the fol-
lowing covariates: prior experience with VKAs (naïve,
experienced, mixed/not reported), study design (commu-
nity, anticoagulation clinic, RCT), study year (from 1990–
2000 and 2001–7, 2008–2013), use of self-management or
not, interpolation method (linear or other), geographic re-
gion (North America [United States and Canada], Europe/
UK, Asia, multinational, other) and duration of VKA
treatment (<1 year, ≥1 year). No hierarchy was used in
the model for these covariates.
The weighted proportion of thromboembolic and hemor-
rhagic events occurring outside of the INR range for each
study group was also calculated. For this analysis, the
numerator was the number of thromboembolic events
occurring below an INR of 2.0 or the number of hemor-
rhagic events above an INR of 3.0. The denominators were
the total number of thrombotic or hemorrhagic events for
each study group. Ninety-five percent CIs were calculated
for each proportion using the Wilson score method without
continuity correction. Again, all studies were pooled using a
random-effects model. Since not all studies measured INR
values at the exact time of adverse outcomes, we conducted
two separate analyses, one pooling studies regardless of
the elapsed time between the INR measurement and the
adverse event; and a second (sensitivity analysis) including
only those studies specifically stating an INR was mea-
sured within 48 hours of the event.
For all meta-analyses, statistical heterogeneity was de-
termined using the I2 statistic (with an I2 > 50% signify-
ing an important degree of statistical heterogeneity) and
publication bias was assessed using the Egger’s weighted
regression statistic (with a p < 0.05 suggesting a higher
likelihood of publication bias) and through review of fun-
nel plots (scatterplots of effect size against standard error,
where the each dot represents a study effect estimateand the vertical line represents the pooled effect).
Statistical analyses were performed using StatsDirect
version 2.7.6 (StatsDirect Ltd., Cheshire, England), SAS,
version 9.2 (SAS Institute Inc., Cary, NC), and SPSS 15.0
for Windows (SPSS, Inc, Chicago, IL).
Results
We identified 5,326 citations, of which 5,231 were ex-
cluded (Figure 1). Ninety-five articles met our inclusion
and exclusion criteria [11-103]. Sixty-eight studies re-
ported measures of INR control representing 87 VKA
study arms, and 43 studies reported an INR at or near
the time of the adverse event (16 studies reported both
and were included in both analyses).
Of the 87 VKA study groups that reported a measure
of INR control, 17 reported data on patients with no
prior VKA exposure whereas 47 enrolled patients who
were VKA-experienced and 23 did not report prior VKA
exposure data or had mixed enrollment. Twenty-eight
VKA groups were from RCTs, 27 were conducted in an
anticoagulation clinic setting, and 32 were in a commu-
nity practice setting (Table 1). Thirty-nine VKA study
groups were recruited in Europe/UK, 5 from Asia, 13
were multinational, 1 from Israel and 29 from North
America. The mean age ranged from 62 to 92 years
(median, 72 years), the number of VKA-treated patients
ranged from 55 to 11,770 (median, 249), and the person-
years of VKA therapy ranged from 17 to 30,188 (median,
399). Of the 43 identified studies that reported an INR
with an adverse event, 16 were RCTs, 14 were conducted
in an anticoagulation clinic, and 13 were from community
practice with the number of VKA-treated patients ranged
from 55 to 9,217 (median, 288) (Table 1).
For the first meta-analysis, 78 out of 87 (90%) study
groups reported a TTR and 55 (63%) reported the time
spent below and above range; 22 of 87 (25%) study groups
reported a PINRR and 21 (24%) reported the percent of
INR measures below and above range (Table 2). Thirteen
study groups (15%) reported both TTR and PINRR. Over-
all, patients spent 61% of their TTR (95% CI, 59–62%),
25% (95% CI, 23–27%) below, and 14% (95% CI, 13-15%)
above range. Similarly for PINRR, 56% of INR measure-
ments were in the therapeutic range (95% CI, 53–59%),
26% (95% CI, 23–29%) below and 13% (95% CI, 11-17%)
above range. Statistical heterogeneity was observed to
be high between the groups included in these analyses
(I2 ≥ 97%). The likelihood of publication bias appeared
low for TTR, time above range, PINRR, and proportion
of INR measurements below and above range. However,
publication bias was deemed more likely for the time
below range analysis (Egger’s p = 0.03) (Additional file 1).
Upon meta-regression to determine how study-level
factors influenced TTR, community VKA management
























n Additional records identified 
through other sources
(n=20)





Not a RCT/OBS study (n=2901)
Not in a AF population (n=861)
<50 VKA-treated subjects (n=240)
<3 months of therapy (n=180)
Full-text articles assessed 
for eligibility
(n = 1144)
Full-text articles excluded (n=1049)
Duplicates (n=61)
Foreign Language (n=111)
Not a RCT/OBS study (n=186)
Not in an AF population (n=442)
<50 VKA-treated subjects (n=26)    
<3 months of therapy (n=71)
Endpoint not reported (n=102)
INR not in prespecified range (n=30)
Patient cohorts repeated (n=20)
A total of 95 articles included:
68 studies with 87 VKA-treated study arms 
with TTR or PINRR reported
43 studies with an INR reported with the 
adverse event 
(16 studies reported both)
Records identified through 
database searching
Medline (n = 3260)
Embase (n = 1090)
CCTR (n=956)
Figure 1 Flow diagram showing results of the literature search. CCTR = Cochrane Central Register of Controlled Trials; RCT = randomized
controlled trial; OBS = observational; AF = atrial fibrillation; VKA = vitamin K antagonist; INR = international normalized ratio; TTR = time in therapeutic
range; PINRR = proportion of INR measurements in range.
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European/UK study patients spent more time in range
than North American study patients, and the VKA-naïve
(and mixed/not reported) spent less time in range than
VKA-experienced patients (Table 3). For PINRR, no study-
level factor was found to be significantly different than the
referent upon meta-regression (p > 0.05) (Table 4).
In the second meta-analysis, 30 of 43 studies (70%) re-
ported an INR measure with thromboembolic events, 21
(49%) reported an INR with ischemic stroke, 32 (74%)
reported INRs with major hemorrhage, and 16 (37%) re-
ported an INR with ICH. INR data was incomplete in
58% of the studies that reported adverse events; not all
events were reported with an INR measure. Thirty percentof the studies used previously reported INRs, allowing
INR measures from 3 days up to 12 days prior to be con-
sidered as temporally related to the adverse event.
Overall, 57% of the thromboembolic events occurred
at an INR <2.0 (95% CI, 50-64%) and 42% of hemor-
rhagic events occurred at an INR >3.0 (95% CI, 35 – 51%)
(Figures 2 and 3). A high degree of heterogeneity was
present for studies that reported thromboembolic and
hemorrhagic events (I2 = 80% and 77% respectively); how-
ever, the presence of publication bias was deemed low
(Egger’s p = 0.31 and p = 0.69, respectively) (Additional
file 1). When ischemic stroke and ICH were evaluated
separately from other events, we found that 56% of ische-
mic strokes (95% CI, 48 – 64%) and 45% of ICHs (95% CI,
Table 1 Demographics of included studies







Abdelhafiz 2004 [11] PD/AC clinic 402 72 0% Europe Linear N 19 (637) W
Abdelhafiz (<75) 2008 [12]
PD/AC clinic
203 64
0% Europe Linear N
19 (321)
W
Abdelhafiz (≥75) 2008 [12] 199 80 19 (315)
Akdeniz 2005 [13] PD/Community 208 66 NR Turkey - - - W
Albers 2005 [14] RCT 1962 72 85% N. America Linear N 20 (3270) W
Anderson 2004 [15] RD/AC clinic 87 NR 100% N. America NR N 12 (87) W
Ansell (Italy) 2007 [16] RD/AC clinic 177 72
100% Multinational Linear N
12 (177) W
Ansell (Spain) 2007 [16] RD/AC clinic 218 72 12 (218) A
Ansell (US) 2007 [16] RD/Community 686 75 12 (686) W
Ansell (Canada) 2007 [16] RD/Community 152 74 12 (152) W
Ansell (France) 2007 [16] RD/Community 278 73 12 (278) F
Aronow 1999 [17] PD/Community 125 83 NR N. America NR N 34 (354) W
Boulanger 2006 [18] RD/Community 6454 68 65% N. America Linear N 12 (6454) W
Burton (<75) 2006 [19]
RD/Community
260
NR Mixed Europe Linear N
25 (539)
W
Burton (>75) 2006 [19] 341 15 (414)
Cafolla (Manual) 2011 [20] RD/Community 576 NR 100% Europe Linear N 8 (384) A,W
Cafolla 2012 [21] PD/AC clinic 57 85 100% Europe Linear N 18 (86) W
Cheung 2005 [22] RD/Community 555 70 100% Asia - N 19 (893) W
Chung 2011 [23] RCT 75 65 55% Asia Linear N 3 (19) W
Connolly 1991 [24] RCT 187 68 0% N. America Linear N 15 (234) W
Connolly 2006 [25] RCT 3371 70 78% N. America Other N 15 (4214) NR
Copland 2001 [26] RD/AC Clinic 328 70 100% UK - N 21 (458) W
Currie (stable) 2005 [27]
RD/Community
787 74
100% Europe Linear N
35 (2282)
W
Currie (unstable) 2005 [27] 726 78 35 (2105)
Dentali 2012 [28] PD/AC Clinic 221 75 100 Europe - N 3 (663) W
DiMarco 2005 [29] RCT NR 70 NR N. America - N 42 (−) W
Dimberg (control SP) 2012 [30] RD/Community 84 69
100% Europe Linear N
12(84)
W
Dimberg (control ACC) 2012 [30] RD/AC clinic 271 72 12(271)
EAFT 1995 [31] RCT 214 71 0% Europe - N 24 (377) W,A,F
Ellis 2009 [32] RCT 66 68 97% N. America Linear N 3 (17) T
Evans 2000 [33] PD/AC clinic 288 76 0% Europe NR N 24 (576) W
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Ezekowitz 2007 [35] RCT 70 69 100% Multinational NR N 3 (18) W
Fang 2004 [36] RD/AC Clinic 170 78 100 N. America - N - W
Gallagher 2011 [37] RD/Community 18113 73 72% Europe Linear N 20 (30188) W






Garcia (exp) 2013 [38] 5193 70 100% 22 (9521)
Gladstone 2009 [39] RD/Community 423 78 100 N. America - N - W
Go 2003 [40] RD/AC clinic 7445 71 Mixed N. America Linear N 21 (12958) W
Gullov 1998 [41] RCT 170 73 0% Europe Linear N 25 (355) W
Gullov 1999 [42] RCT 170 73 0 Europe Linear N 25 (355) W
Gurwitz 1997 [43] RD/Community 117 83 32% N. America Linear N 12 (117) W
Hannon 2011 [44] PD/Community 43 77 100 Europe - N - W
Hart 2011 [45] RCT 523 NR 0 N. America - N 13 (575) W
Heidinger 2000 [46] RD/Community 753 62 100% Europe NR Y 12 (769) NR
Hellemons 1999 [47] RCT 131 70 0 Europe - N 32 (354) P,A
Ho (hypertension) 2011 [48]
RD/Community
278 70
NR Multinational Linear N
48 (1112)
W
Ho (no HTN) 2011 [48] 198 69 48 (792)
Holmes 2009 [49] RCT 244 73 100% Multinational NR N 18 (366) W
Hori 2012 [50] RCT 250 71 90% Asia Linear N 30 (625) W
Hylek 2003 [51] RD/Community 188 76 100 N. America - N - W
Hylek 2007 [52] PD/AC clinic 472 77 0% N. America Linear N 12 (360) W
Jacobs 2009 [53] RD/Community 90 NR 85% N. America Linear N 12 (90) W
Jones 2005 [54] RD/Community 2223 72 100% Europe Linear N 31 (5743) W
Kalra 2000 [55] PD/AC clinic 167 77 0% Europe Linear N 24 (296) W
Kim 2009 [56] RD/AC clinic 129 64 100% Asia Other N 24 (258) W
Kim 2010 [57] PD/AC clinic 499 73 100% N. America Linear N 5 (208) W
Kulo (warfarin) 2009 [58]
PD/Community
60 66
100% Europe NR N
12 (60) W
Kulo (acenocoumarol) 2009 [58] 57 68 12 (57) A
Lee 2012 [59] RD/Community 200 67 NR Asia Linear N 42 (700) W
Malik 2000 [60] RD/AC clinic 247 68 100% N. America Other N 13 (268) W
Mant 2007 [61] RCT 488 82 40% Europe Linear N 32 (1301) W
Matchar (control) 2002 [62] RCT 317 76
NR N. America Linear N
9 (238)
W
Matchar (prior to ACC) 2002 [62] PD/AC clinic 363 75 9 (272)
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McCormick 2001 [64] RD/Community 174 87 100% N. America Linear N 12 (174) W
Melamed 2011 [65] RD/Community 906 72 100% Israel Linear N 10 (769) W
Menzin 2005 [66] RD/AC clinic 600 72 63% N. America Linear N 11 (525) W
Morocutti 1997 [67] RCT 454 72 NR Europe - N 12 W
Neree 2006 [68] RD/Community 395 74 100% Europe Linear N 4 (132) P,A,W
Nichol (ACC) 2008 [69] RD/AC clinic 351
NR 100% N. America Linear N
31 (920)
W
Nichol (UC) 2008 [69] RD/Community 756 18 (1165)
Njaastad 2006 [70] RD/AC clinic 421 NR 0% Europe Linear N 14 (475) W
Nozawa 2001 [71] PD/Community 156 68 100 Asia - N 22 (286) W
Ogawa 2011 [72] RCT 75 72 0 Asia Linear N 3 (210) W
Okumura (<70) 2011 [73] PD/Community 208 NR 100% Asia Linear N 23 (399) W
Olsson 2003 [74] RCT 1703 70 73% Multinational NR N 16 (2271) W
Ono 2005 [75] PD/Community 63 76 0 Asia Linear N 28 (145) W
Patel 2011 [76] RCT 7133 73 63% Multinational Linear N 20 (11888) W
Pengo 1998 [77] RCT 153 74 0% Europe Linear N 14 (179) W
Pengo 2001 [78] PD/AC Clinic 433 68 0 Europe Linear N 17 (615) W,A
Pengo 2010 [79] RCT 132 79 0% Multinational Linear N 64 (704) W
Perez-Gomez 2004 [80] RCT 237 70 0% Europe NR N 33 (556) A
Poli 2007 [81] PD/AC clinic 290 82 100% Europe Linear N 34 (814) NR
Poli 2009 [82] PD/AC Clinic 783 75 0% Europe Linear N 39 (2567) W
Poli 2009 [83] PD/AC clinic 578 75 100% Europe Linear N 38 (1854) NR
Poli 2009 [84] PD/AC clinic 780 75 100 Europe Linear N 36 (2406) W
Poller (Manual) 2008 [85] RCT 2967 67 0% Multinational Linear N 17 (4203) W, A, P
Sadanaga 2010 [86] PD/Community 259 74 100 Asia - N 25 (544) W
Samsa (ACC) 2000 [87] RD/AC Clinic 43
69 NR N. America Linear N
9 (32)
WSamsa (Rochester) 2000 [87] RD/Community 61 9 (46)
Samsa (R. Triangle) 2000 [87] RD/Community 125 9 (94)
Schwammenthal 2010 [88] PD/Community 111 76 100 Israel - N - W
Sconce (vitamin K) 2007 [89]
RCT
35 75
100% Europe Linear N 6 (18) W
Sconce (placebo) 2007 [89] 35 74
Shen 2007 [90] RD/Community NR 72 55% N. America NR N 40 (24179) W
Singer 2009 [91] RD/Community 9217 77 100 N. America - N 72 (33497) W
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Sullivan (men) 2012 [93] 2466 68 86% 42 (8631)
Tincani 2009 [94] PD/AC Clinic 90 92 100% Europe Linear N 12 (90) W
Van Spall 2012 [95] RCT 6022 72 47% Multinational Linear N 24 (12044) W






Voller (UC) 2005 [96] 101 64 N
Walker (MHC) 2011 [97]
RD/AC Clinic
22
NR 100% N. America Linear N
12 (22)
W
Walker (no MHC) 2011 [97] 62 12 (62)
Wieloch (AF) 2011 [98] RD/Community 11770 73 100% Europe Linear N 12 (11770) W
Weitz 2010 [99] RCT 250 66 35% N. America Linear N 3 (63) W
Wyse 2002 [100] RCT NR 70 NR N. America - N 42 W
Yamaguchi 2000 [101] RCT 55 66 NR Asia - N 22 (101) W
Yasaka 2001 [102] PD/Community 88 100 Asia - N 22 (161) W
Yousef 2004 [103] RD/Community 739 73 100% Europe NR N 24 (1484) W
VKA = vitamin K antagonist; RCT = randomized controlled trial; RD = retrospective design; PD = prospective design; AC clinic = anticoagulation clinic; AF = atrial fibrillation; NR = not reported; N = North; VKA = Vitamin K

















Table 2 Time in range and percentage of INR values in range and major adverse event rates
Study, year N TTR, % PINRR, % Event rate, % per patient-year
In range Below range Above range In range Below range Above range Bleeding ICH Ischemic stroke
Abdelhafiz 2004 [11] 402 66 19.7 14.3 - - - 1.7 - -
Abdelhafiz (<75) 2008 [12] 203 58 16 26 - - - 1.6 0 -
Abdelhafiz (≥75) 2008 [12] 199 58 16 26 - - - 1.9 0 -
Albers 2005 [14] 1962 68 20 12 - - - 2.8 0.2 1.1
Anderson 2004 [15] 87 - - - 60.4 25.2 14.3 -
Ansell (Italy) 2007 [16] 177 68.9 21 10.1 60 26.3 13.6 - - -
Ansell (Spain) 2007 [16] 218 64.4 18.6 17 59 23.3 17.7 - - -
Ansell (US) 2007 [16] 686 57 29.1 13.9 50.8 32 17.3 - - -
Ansell (Canada) 2007 [16] 152 61 25.9 13.1 58.4 27.6 14 - - -
Ansell (France) 2007 [16] 278 58.1 15.4 26.5 51.3 19.7 29 - - -
Aronow 1999 [17] 125 - - - 68 26 6 - - 11.3
Boulanger 2006 [18] 6454 48 38 14 - - - 2.8 - -
Burton (<75) 2006 [19] 260 68 17 15 - - - 2.8
Burton (>75) 2006 [19] 341 68 19 13 - - - 2.4
Cafolla (Manual) 2011 [20] 576 60.4 - - - - - - - -
Cafolla 2012 [21] 57 64.4 - - - - - 0 - -
Chung 2011 [23] 75 45.1 43.9 10.9 - - - 10.5 0 0
Connolly 1991 [24] 187 43.7 39.6 16.6 - - - 2.1 0.4 2.1
Connolly 2006 [25] 3371 63.8 20.8 15.4 - - - 2.2 - 1.0
Currie (stable) 2005 [27] 787 74.9 - - - - - 0.4 - -
Currie (unstable) 2005 [27] 726 55.7 - - - - - 1.2 - -
Dimberg (UC) 2012 [30] 84 64.3 - - - - - - - -
Dimberg (ACC) 2012 [30] 271 73.6 - - - - - - - -
Ellis 2009 [32] 66 71.4 - - 70.7 16.0 13.3 5.8
Evans 2000 [33] 288 55 26 19 - - - 3.1 0.5 5.5
Evans 2001 [34] 214 66 - - - - - 3.1 0.7 4.2
Ezekowitz 2007 [35] 70 57.2 - - - - - 0 - -
Gallagher 2011 [37] 18113 63.1 20.7 16.2 - - - - - -
Garcia (naïve) 2013 [38] 3888 61.4 - - - - - 3.0 0.8 -
Garcia (exp) 2013 [38] 5193 69.1 - - - - - 3.2 0.8 -
Go 2003 [40] 7445 62.5 26.8 10.7 - - - 1.5 0.4 1.1

















Table 2 Time in range and percentage of INR values in range and major adverse event rates (Continued)
Gurwitz 1997 [43] 117 39.6 44.8 15.6 - - - - - -
Heidinger 2000 [46] 753 - - - 69.5 23.5 7.0 1.7 - -
Ho (HTN) 2011 [48] 278 49.7 45.4 4.9 - - - 1.7 0.5 2.2
Ho (no HTN) 2011 [48] 198 49.8 44.2 6.0 - - -
Holmes 2009 [49] 244 66 - - - - - 2.7 - 1.6
Hori 2012 [50] 250 - - - 51.8 43.8 4.2 0.8 0.3
Hylek 2007 [52] 472 58 29 11 - - - 7.2 2.5 -
Jacobs 2009 [53] 90 49 35 15 - - - 5.6
Jones 2005 [54] 2223 68.9 16.7 15.4 53.4 - - - - -
Kalra 2000 [55] 167 61 26 13 - - - 1.4 0.3 2.0
Kim 2009 [56] 129 - - - 60.9 31.2 9.1 0
Kim 2010 [57] 499 73.4 - - - - - - - -
Kulo (warfarin) 2009 [58] 60 - - - 51.8 42.8 5.4 - - -
Kulo (acenocoum) 2009 [58] 57 - - - 53.6 35.9 10.5 - - -
Lee 2012 [59] 200 48.5 - - - - - 6.6 - -
Malik (AF) 2000 [60] 247 58.9 27.4 14.1 - - - - - -
Mant 2007 [61] 488 67 19 14 - - - 1.9 - 0.8
Matchar (control) 2002 [62] 317 52.3 31.8 15.9 - - - 2.1 - -
Matchar (ACC) 2002 [62] 363 55.6 31.2 13.1 - - - 2.2 - -
McBride 2007 [63] 361 56 16 28 - - - - - -
McCormick 2001 [64] 174 51 36 13 - - - - - -
Melamed 2011 [65] 906 48.6 32.0 19.3 - - - - - -
Menzin 2005 [66] 600 62 25 13 - - - 3.6 - 1.0
Neree 2006 [68] 395 53 - - 52.8 8.7 38.5 4.4 - -
Nichol (ACC) 2008 [69] 351 68 21 11 - - - 2.3 - -
Nichol (UC) 2008 [69] 756 42 49 9 - - - 6.3 - -
Njaastad 2006 [70] 421 71.5 - - - - - 0.8 - -
Okumura (<70) 2011 [73] 208 46 51 2 - - - - - -
Olsson 2003 [74] 1703 66 - - - - - 2.2 - 1.9
Patel 2011 [76] 7133 55 - - - - - 3.4 0.7 -
Pengo 1998 [77] 153 70 18 12 - - - 2.8 0.6 0
Pengo 2010 [79] 132 65 25 9 - - - 3.0 - -

















Table 2 Time in range and percentage of INR values in range and major adverse event rates (Continued)
Poli 2007 [81] 290 69 15 16 - - - 2.1 1.4 -
Poli 2009 [82] 783 71 14 15 - - - 1.4 0.7 0.9
Poli 2009 [83] 578 68 16 16 - - - - - -
Poller (Manual) 2008 [85] 2967 66.2 - - - - - - - -
Samsa (ACC) 2000 [87] 43 60.3 25.9 13.8 54.9 26.7 18.3 - - -
Samsa (Rochester) 2000 [87] 61 46.9 33.9 19.3 43.6 33.5 22.9 - - -
Samsa (R. Triangle) 2000 [87] 125 35.6 52.1 12.2 34.2 51.0 14.8 - - -
Sconce (vitamin K) 2007 [89] 35 87 - - - - - - - -
Sconce (placebo) 2007 [89] 35 78 - - - - - - - -
Shen 2007 [90] NR 54.5 36.3 9.2 - - - - 0.5 -
SPAF III 1996 [92] 523 - - - 61 25 14
Sullivan (women) 2012 [93] 1594 60 29 11 - - - - - 0.8
Sullivan (men) 2012 [93] 2466 63 26 14 - - - - - 0.5
Tincani 2009 [94] 90 66 19 14 - - - 5.5 3.3 2.2
Van Spall 2012 [95] 6022 64 22 13 - - - - - -
Voller (self-mgmt) 2005 [96] 101 72.4 13.6 14 67.8 15.2 17.0 2.9 - -
Voller (UC) 2005 [96] 101 63.6 19.5 16.9 58.5 22.1 19.4 0 - -
Walker (MHC) 2011 [97] 22 56.8 34.2 9.0 - - - - - -
Walker (no MHC) 2011 [97] 62 65.9 30.7 3.4 - - - - - -
Wieloch (AF) 2011 [98] 11770 76.5 - - - - - 2.6 - -
Weitz 2010 [99] 250 49.7 - - - - - 1.6 - -
Yousef 2004 [103] 739 - - - 62.8 22.9 14.3 1.9 - -
AC = Anticoagulation; AF = atrial fibrillation; ICH = Intracranial Hemorrhage; HTN = Hypertension, INR = international normalized ratio; MGMT =Management; N = Number; SP = Standard Practice; TTR = time in the

















Table 3 Results of traditional meta-analysis and meta-regression analyses of time in the therapeutic range
Time spent in therapeutic range
Study-level factors No. (%) Unadjusted pooled mean upon




All study groups 78 (100) 61 (59 to 62) NA NA
Study setting
AC Clinic 25 (32.1) 64 (62 to 66) 7.2 (3.2 to 11.2) <0.001
RCT 26 (33.3) 63 (61 to 65) 9.1 (4.3 to 13.9) <0.001
Community 27 (34.6) 55 (52 to 59) Referent
Study year
1990-2000 10 (12.8) 53 (46 to 61) −4.3 (−10.2 to 1.6) 0.16
2001-2007 34 (43.6) 64 (62 to 65) 2.2 (−1.7 to 6.1) 0.28
2008-2013 34 (43.6) 60 (57 to 63) Referent
Interpolation method
NR/Other 11 (14.1) 63 (60 to 65) −2.1 (−6.8 to 2.6) 0.38
Linear 67 (85.9) 60 (59 to 62) Referent
Self-management
No 77 (98.7) 60 (58 to 62) −6.8 (−23.7 to 10.1) 0.43
Yes 1 (1.3) 72 (68 to 77) Referent
Geographic region
Europe/UK 35 (44.9) 67 (64 to 69) 9.7 (6.0 to 13.4) <0.001
Asia 3 (3.8) 47 (44 to 49) −5.5 (−14.7 to 3.7) 0.24
Other 1 (1.3) 49 (46 to 52) −3.0 (−16.1 to 10.1) 0.65
Multinational 13 (16.7) 61 (57 to 65) 1.8 (−4.1 to 7.7) 0.55
North America 26 (33.3) 55 (50 to 60) Referent
VKA experience
NR/Mixed 21 (26.9) 54 (49 to 60) −4.6 (−8.3 to −0.9) 0.02
No 17 (21.8) 63 (60 to 66) −5.3 (−9.6 to −1.0) 0.02
Yes 40 (51.3) 63 (60 to 66) Referent
Duration of VKA treatment
≥1 year 59 (75.6) 62 (60 to 63) 2.7 (−1.7 to 7.1) 0.23
<1 year 19 (24.4) 58 (52 to 65) Referent
AC = anticoagulation; CI = confidence interval; NA = not applicable; No. = number of study arms; NR = Not Reported; RCT = randomized controlled trial; UK = United
Kingdom, VKA = Vitamin K Antagonists.
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a high degree of heterogeneity was still present (I2 = 76%
and 85%, respectively) (Figures 4 and 5). Furthermore, when
studies that allowed previously reported INRs (more than
48 hours prior to an event) were excluded, we found a
higher proportion of events that occurred outside the
therapeutic range for 59% of thromboembolic events (95%
CI, 51 – 66%) and 47% of hemorrhagic events (95% CI,
37 – 58%).
Discussion
In a pooled analysis of AF studies performed worldwide
between 1990 and June 2013, we found patients spent
only 61% of their TTR and only 56% of their measuredINRs were in range. Moreover, when patients were out
of range, they were more likely to be below range and at
an increased risk of thrombosis, as compared to being
above range with an increased risk of bleeding. While,
thromboembolic and hemorrhagic events did occur in
patients with a therapeutic INR; we demonstrated more
than half of all thromboembolic events occurred when
the INR was less than 2.0 and more than 40% of all
hemorrhagic events happened at an INR > 3.0. As such,
the efficacy and safety of VKAs appear strongly tethered
to the quality of INR control achieved.
Our meta-regression analyses showed three important
findings. First, patients having their VKAs managed in
the community setting spent significantly less TTR when
Table 4 Results of traditional meta-analysis and meta-regression analyses of proportion of INR measurements in range
Proportion of INR measurements in range
Study-level factors No. (%) Unadjusted pooled mean upon




All study groups 24 (100) 56 (53 to 59) NA NA
Study setting
AC Clinic 5 (20.8) 60 (58 to 62) 6.9 (−0.02 to 15.2) 0.13
RCT 5 (20.8) 61 (54 to 68) 5.6 (−0.06 to 17.0) 0.36
Community 14 (58.3) 54 (50 to 57) Referent
Study year
1990-2000 6 (25.0) 54 (46 to 64) 3.3 (−25.3 to 31.9) 0.82
2001-2007 13 (54.2) 56 (54 to 59) −2.8 (−14.8 to 9.2) 0.65
2008-2013 5 (20.8) 56 (51 to 62) Referent
Self-management
No 22 (91.7) 55 (43 to 57) −9.3 (−32.4 to 13.8) 0.45
Yes 2 (8.3) 69 (67 to 72) Referent
Geographic region
Europe/UK 13 (54.2) 57 (54 to 60) −1.7 (−10.7 to 7.3) 0.71
Asia 2 (8.3) 56 (48 to 66) −8.8 (−26.4 to 8.8) 0.32
Other 0 (0) NA NA NA
Multinational 0 (0) NA NA NA
North America 9 (37.5) 54 (48 to 62) Referent
VKA experience
NR/Mixed 5 (20.8) 51 (41 to 63) −5.7 (−34.7 to 23.3) 0.83
No 3 (12.5) 63 (55 to 73) 7.9 (−15.2 to 31.0) 0.65
Yes 17 (70.8) 56 (54 to 59) Referent
Duration of VKA treatment
≥1 year 17 (70.8) 57 (54 to 60) 9.1 (−0.5 to 18.7) 0.09
<1 year 7 (29.2) 53 (44 to 65) Referent
AC = anticoagulation; CI = confidence interval; NA = not applicable; No. = number of study arms; NR = not reported; RCT = randomized controlled trial; UK = United
Kingdom; VKA = Vitamin K Antagonists.
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http://www.thrombosisjournal.com/content/12/1/14compared to patients managed in an anticoagulation clinic
or in a RCT setting. This data supports the growing body
of literature demonstrating that patients whose care is
managed in an anticoagulation clinic have better outcomes
(improved TTR, lower rates of major bleeding and throm-
bosis, and decreased health care costs) than those managed
in community practice [104-106]. The improved INR
control in RCTs and anticoagulation clinics may be the
result of increasing the frequency of monitoring, providing
more organized care and focusing more on improving
poor VKA-drug persistence (as low as 68% at 6-months)
[107,108] than typically done in community settings. Un-
fortunately, not all patients receiving a VKA have access
to anticoagulation clinics [109]. In fact, it is estimated that
only about one-third of patients receiving a VKA in the
US have access to an anticoagulation clinic due to time,
distance, economic or other access-to-care issues. Second,patients who were VKA-naive spent significantly less time
in the therapeutic range than VKA-experienced patients.
This is likely a result of poorer INR control early on
in treatment, as clinicians attempt to control the INR
within the narrow therapeutic window without any prior
knowledge of the patient’s-specific dosing requirements.
It may also suggest that patients learn to manage their
VKA better over time. This observation may warrant
researchers to stratify analyses according to whether
patients are newly initiated to warfarin or experienced
warfarin patients. Finally, people in North America spent
significantly less time in the therapeutic range than those in
Europe or the UK. This may be a result of North America’s
near exclusive use of warfarin, which has been shown in
previous analyses to result in as much as a 9% lower TTR
compared to other VKAs [6], as well as, North America’s
less wide-spread use of proven strategies to increase
Figure 2 Results of random-effects meta-analysis of the proportion of thromboembolic events that occurred when INRs were below
2.0. The squares represent individual studies, and the size of the square represents the weight given to each study in the meta-analysis. Error bars
represent 95% confidence intervals. The diamond represents the combined results. List of studies shows name of first author and year of publication.
CI = Confidence Interval.
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[6,8,9,109] and patient self-monitoring [6].
Our systematic review and meta-analysis supports and
extends the knowledge of VKA use in contemporary prac-
tice. Our TTR or PINRR results are in general agreement
with the systematic reviews by van Walraven et al. [6] and
Cios et al. [9], but these analyses included all therapeutic
indications for VKAs, which lowers their applicability for
an AF-specific population. The meta-analyses by Baker
et al. [8] and Wan et al. [7] focused on AF only popula-
tions, but each had some limitations. The Baker meta-
analysis was limited to a United States population, and
therefore, contained only 8 studies. Despite this, they did
find that care within an anticoagulation clinic yielded a
higher TTR than usual care in the community, a finding
we extend into the worldwide AF population as well. The
Wan meta-analysis was published in 2008, evaluated a
worldwide AF population and found similar TTR and
PINRR results to our own. However, they only included
47 VKA groups from 38 published studies. They found
that TTR was significantly correlated with PINRR in retro-
spective studies and TTR was significantly negatively cor-
related to both major hemorrhage and thromboembolic
events. Given the intense focus on thromboembolism incontemporary practice, our literature search was able to
almost double the number of articles included in the
Wan et al. by updating the search to 2013. Over the
5 years since the publication of Wan et al.’s meta-
analysis, we found the TTR and PINRR to be only slightly
increased (overall TTR increased from 57% to 61% and
PINRR from 51 to 56%) [7]. This suggests that we still
have a long way to go to enhance the quality of INR con-
trol. Our findings that the majority of thromboembolic
events happen in AF patients when the INR is less than
2.0 and more than 40% of hemorrhages occur when an
INR is greater than 3.0 confirms the findings from the
systematic review of Oake et al. [10]. Their systematic
review did not limit the studies to an AF population and
was published in 2009, so our findings through June
2013 in the target AF population extend knowledge in this
area as well.
There are several limitations of our meta-analysis worth
discussion. First, the potential for publication bias and
possibility of missed eligible articles could exist. However,
we consider this risk to be minimized due to our system-
atic search strategy and manual backwards citation track-
ing. In addition, having such a large cadre of studies, as
we do in our meta-analysis, minimizes the impact that a
Figure 4 Results of random-effects meta-analysis of the proportion of ischemic strokes that occurred when INRs were below 2.0. The
squares represent individual studies, and the size of the square represents the weight given to each study in the meta-analysis. Error bars
represent 95% confidence intervals. The diamond represents the combined results. List of studies shows name of first author and year of publication.
CI = Confidence Interval.
Figure 3 Results of random-effects meta-analysis of the proportion of major hemorrhagic events that occurred when INRs were above
3.0. The squares represent individual studies, and the size of the square represents the weight given to each study in the meta-analysis. Error bars
represent 95% confidence intervals. The diamond represents the combined results. List of studies shows name of first author and year of publication.
CI = Confidence Interval.
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Figure 5 Results of Random-Effects Meta-Analysis of the Proportion of Intracranial Hemorrhages That Occurred When INRs Were
Above 3.0. The squares represent individual studies, and the size of the square represents the weight given to each study in the meta-analysis.
Error bars represent 95% confidence intervals. The diamond represents the combined results. List of studies shows name of first author and year
of publication. CI = Confidence Interval; ICH = Intracranial hemorrhage.
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Another limitation of our analysis includes the fact that
very few identified studies evaluated PINRR. As a result,
our meta-regression analysis was likely underpowered;
although similar trends could be seen to TTR. Future
evaluation of PINRR should be conducted when there is
a sufficient literature base to make firmer conclusions.
Another limitation of our analysis is the possibility of a
language bias; as we only included English language
studies which may not represent all of the published
evidence. Finally, there was a high degree of statistical
heterogeneity observed in our analyses, suggesting that
the included studies varied clinically and/or methodo-
logically. However, this was one of our rationales for
conducting meta-regression. In our meta-regression ana-
lyses, we found some potential explanations for the identi-
fied heterogeneity; although there may still be additional
factors that we could not think to evaluate or for which
there is insufficient data to allow evaluation.Conclusions
Patients on VKAs for thromboembolism prevention in AF
are frequently outside the normal INR range and tend to
be under-anticoagulated rather than over-anticoagulated.
While, thromboembolic and hemorrhagic events do occur
patients with a therapeutic INR; patients with an INR < 2.0
make up many of the cases of thromboembolism, while
those with an INR > 3.0 make up many of the cases of
major hemorrhage. Managing anticoagulation outside of a
clinical trial or anticoagulation clinic is associated with
poorer INR control as is initiation of therapy in patients
who are VKA-naïve. Patients in Europe/UK have better
INR control than those in North America.Additional file
Additional file 1: Medline search strategy and forest plots for time
and percent of INRs in, below and above range.Abbreviations
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